UROLOGY JOURNAL, cilt.17, sa.5, ss.517-521, 2020 (SCI-Expanded)
Purpose: The present study was designed to compare the efficacy of alfuzosin therapy as an alpha-blocker in metabolic syndrome (MetS) and non-MetS patients with moderate lower urinary tract symptoms (LUTS).